Rajakulasingam, Raj K, Farah, N, Huber, P A J, Durham, S R, Clark, A T, Nasser, S M and Krishna, M T (2017) Practice and Safety of Allergen Specific Immunotherapy for Allergic Rhinitis in the UK National Health Service: A report of 'real world' clinical practice. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. ISSN 1365-2222. This article is available to all HEFT staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their HEFT Athens login IDs
Full text not available from this repository.Abstract
Allergen specific immunotherapy (SIT) alleviates symptoms, improves health-related quality of life and alters the natural course of the disease in patients suffering from allergic rhinitis. It is currently delivered in the UK National Health Service (NHS) via 2 modalities namely subcutaneous injection immunotherapy (SCIT) and sublingual immunotherapy (SLIT). The latter has a superior safety profile - anaphylaxis is a rare occurrence. Most vaccines currently employed for SIT in the UK NHS are unlicensed and available on a named-patient basis and prescribed in secondary care by a specialist. This article is protected by copyright. All rights reserved.
Item Type: | Article |
---|---|
Additional Information: | This article is available to all HEFT staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their HEFT Athens login IDs |
Subjects: | QW Microbiology. Immunology WD Diseases and disorders of systemic, metabolic or environmental origin > WD300 Hypersensitivity. Allergy |
Divisions: | Clinical Support > Pathology |
Depositing User: | Miss Emily Johnson |
Date Deposited: | 26 Jan 2018 13:51 |
Last Modified: | 26 Jan 2018 13:51 |
URI: | http://www.repository.uhblibrary.co.uk/id/eprint/1461 |
Actions (login required)
![]() |
View Item |